文献速递乳腺癌

绝经后早期乳腺癌延长内分泌治疗决策与不良事件影响

Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer.
PubMed 文献 · Eur J Cancer · 2018-04-07

基于IDEAL试验分析绝经后激素受体阳性早期乳腺癌患者参与延长来曲唑治疗的决策因素及早期停药影响。淋巴结状态、年轻年龄和辅助化疗与更高入组相关;不良事件、原内分泌治疗类型及间隔与早期停药相关,抑郁感受最常见。早期停药未与更差DFS相关(HR=1.02,95%CI 0.76-1.37)。

要点

  • 淋巴结状态、年轻年龄和辅助化疗与更高入组延长治疗相关。
  • 不良事件、原内分泌治疗类型及间隔与早期停药相关,抑郁感受最常见。
  • 早期停药未与更差DFS相关(HR=1.02,95%CI 0.76-1.37)。

核心结论

  • 风险因素与延长内分泌治疗试验入组强相关,而患者体验是早期停药的最重要因素,且早期停药未影响DFS。

研究设计与样本

  • IDEAL试验中绝经后患者完成5年内分泌治疗后随机接受2.5或5年延长来曲唑;亚组此前参与TEAM试验,探索入组决定因素。

主要发现

  • 淋巴结状态、年轻年龄和辅助化疗与更高IDEAL入组显著相关。
  • IDEAL队列中,不良事件、原内分泌治疗类型及间隔与早期停药相关。
  • 抑郁感受(56%)是最常与早期停药相关的不良事件。
  • 早期停药未与更差DFS相关(HR=1.02,95%CI 0.76-1.37)。

临床怎么用

  • 临床决策延长内分泌治疗时需关注患者体验和不良事件,尤其是抑郁感受,以改善治疗持续性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Extended endocrine therapy beyond 5 years for postmenopausal breast cancer has been studied within multiple phase III trials. Treatment compliance in these trials is generally poor. In this analysis, we aimed to determine factors that were associated with participation in the phase III Investigation on the Duration of Extended Adjuvant Letrozole (IDEAL) trial and with early treatment discontinuation, and how this influenced survival outcome. METHODS: In the IDEAL trial, postmenopausal patients were randomised between 2.5 or 5 years of extended letrozole, after completing 5 years of endocrine therapy for hormone receptor-positive early breast cancer. A subgroup of this population participated earlier in the Tamoxifen Exemestane Adjuvant Multinational trial (5 years of exemestane or 2.5 years of tamoxifen followed by exemestane as primary adjuvant therapy) in which we explored which factors were determinative for enrolment in the IDEAL study. In the IDEAL cohort, we evaluated which factors predicted for early treatment discontinuation and the effect of early treatment discontinuation on disease-free survival (DFS). RESULTS: Nodal status, younger age and adjuvant chemotherapy were significantly associated with higher enrolment in the IDEAL trial. In the IDEAL cohort, adverse events (AEs), the type of primary endocrine therapy and the interval between primary and extended therapy were associated with early treatment discontinuation. Among the reported AEs, depressive feelings (56%) were most frequently associated with early treatment discontinuation. Early treatment discontinuation was not associated with worse DFS (hazard ratio [HR] = 1.02, 95% confidence interval = 0.76-1.37). CONCLUSIONS: In this analysis, we found that risk factors were most strongly associated enrolment in the IDEAL trial. In contrast, patient experiences were the most significant factors leading to early treatment discontinuation, with no effect on DFS.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, et al. Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer. Eur J Cancer. 2018. PMID: 29635145. doi:10.1016/j.ejca.2018.03.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。